# Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis

> **NCT07678203** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hospital Civil Juan I. Menchaca** · enrollment: 30 (estimated)

## Conditions studied

- Lupus Nephritis (LN)
- Chronic Kidney Disease
- SGLT 2 Inhibitors
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Dapagliflozin (10Mg Tab) along with standard medical therapy
- **DEVICE:** Proteinuria Quantification

## Key facts

- **NCT ID:** NCT07678203
- **Lead sponsor:** Hospital Civil Juan I. Menchaca
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-05-28
- **Primary completion:** 2027-01-28
- **Final completion:** 2027-02-26
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678203, "Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*